CAS 202815-17-6 NY-ESO-1(157–165)peptide

Send Inquiry
CAS 202815-17-6 NY-ESO-1(157–165)peptide
Details
Cancer-testis antigen NY-ESO-1 residues 157-165;
Category: Cancer-testis antigen / HLA-A2 CTL epitope.
Peptide Purity (HPLC) ≥95%
CAS No. 202815-17-6
Structure Linear 9-mer (NY-ESO-1 157-165, SLLMWITQC, HLA-A2)
Solubility DMSO/water cosolvent, PBS
Storage Powder, −20°C, dry, light-protected
Category
Epitope Peptides
Share to
Description

Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 202815-17-6 ny-eso-1(157–165)peptide in China, also supports custom service. Welcome to wholesale bulk high quality cas 202815-17-6 ny-eso-1(157–165)peptide from our factory. Contact us for more details.

 

Description NY-ESO-1 157–165 (SLLMWITQC), one of the most immunogenic cancer-testis epitopes (HLA-A2); widely used for melanoma/sarcoma vaccines and ACT.

 

Product Basic Information Table

 

Product Standard English Name Product Abbreviation / Alias Function Tags (comma-separated) Core Structure Molecular Formula Exact Mass (Da) Average MW (Da) Salt Form Length (aa)
NY-ESO-1 (157-165) peptide (SLLMWITQC, 9-mer, HLA-A*0201 CTL epitope) NY-ESO-1 157-165; ESO 9C; SLLMWITQC; CTAG1B 157-165 cancer-testis antigen, NY-ESO-1, HLA-A2, CD8+ T cell epitope, CTL epitope, cancer vaccine, immunogenic peptide, peptide vaccine, TCR-T target, melanoma, lung cancer, ovarian cancer, gastric cancer, dendritic cell vaccine Full sequence H-Ser-Leu-Leu-Met-Trp-Ile-Thr-Gln-Cys-OH; single-letter SLLMWITQC, 9 aa; free N-terminal amine and free C-terminal carboxyl (free acid); linear peptide, no artificial modifications. Sensitive residues: free thiol Cys x1 (prone to oxidation/disulfide dimerization), Met x1 (sulfoxide), Trp x1 (light-sensitive). C49H79N11O13S2 1093.53 1094.35 powder; typically TFA salt (residual TFA from RP-HPLC); CAS listed as free peptide; confirm actual salt form on COA 9

 

Physicochemical Solubility & Storage Parameters

 

Product Code Appearance Long-term Storage Short-term Storage Solution Stability Solid Powder Stability
PEP-NYESO1-01 White to off-white powder (contains residual TFA) Store desiccated, protected from light, under inert atmosphere (Ar/N2), sealed, at <= -20 C; expected powder stability 2-3 years After reconstitution, aliquot into single-use portions and store at -80 C; avoid repeated freeze-thaw (use within ~1 month); keep on ice and protected from light during handling Protect from light due to Trp; for free Cys use degassed aqueous buffer or a trace of DTT/TCEP to prevent oxidation/disulfide cross-linking. Pre-dissolve in a small volume of DMSO, then dilute with sterile PBS; gentle sonication may help due to hydrophobic Leu/Ile/Met/Trp content. Keep powder dry, oxidation-protected and light-protected. After opening, flush with inert gas and use promptly given the free thiol and methionine; avoid repeated moisture uptake.

 

Functional Description

 

Product Code Frontend Short Summary Detailed Biological Function Description Applicable Research Areas (comma-separated) Targets / Receptors
PEP-NYESO1-01 NY-ESO-1 (157-165) peptide (CAS 202815-17-6) is the 9-mer SLLMWITQC derived from the cancer-testis antigen NY-ESO-1/CTAG1B. It is the classic HLA-A*0201-restricted CD8+ CTL epitope recognized by specific T cells in HLA-A2+ cancer patients and is widely used in cancer vaccines, DC vaccines and TCR-T development. NY-ESO-1 (New York esophageal squamous cell carcinoma-1, CTAG1B) is a prototypical cancer-testis antigen: normally restricted to the testis but re-expressed in melanoma, non-small-cell lung, ovarian, esophageal and gastric carcinomas, making it one of the most attractive shared tumor antigens for immunotherapy. The 157-165 nonapeptide SLLMWITQC is presented on MHC-I (HLA-A*0201) and is recognized by CD8+ cytotoxic T lymphocytes, which lyse antigen-positive tumor cells; it is among the most immunogenic and best-characterized human tumor CTL epitopes. Applications include: (1) in vitro priming/expansion of NY-ESO-1-specific CD8+ T cells and MHC tetramer production; (2) preclinical and clinical peptide/adjuvanted and dendritic-cell vaccine studies; (3) screening and potency testing of NY-ESO-1-specific TCR-T cells, TCR-like antibodies and bispecifics; (4) monitoring antigen-specific T-cell responses after vaccination. Note that the heteroclitic analog SLLMWITQV (C165V) has higher affinity and immunogenicity and is often used as an alternative immunogen; this product is the native SLLMWITQC with a free C-terminal cysteine. tumor immunology, cancer vaccine, T cell epitope mapping, HLA typing studies, DC vaccine, TCR-T therapy, melanoma, lung cancer, ovarian cancer, esophageal cancer, gastric cancer, immune monitoring, CTL killing assay HLA-A*0201 (MHC class I); CD8+ T cell receptor (TCR); NY-ESO-1/CTAG1B

 

 

 

 

Hot Tags: cas 202815-17-6 ny-eso-1(157–165)peptide, China cas 202815-17-6 ny-eso-1(157–165)peptide manufacturers, suppliers, factory, 125366-42-9, BCMA72-80, CAS 125366 42 9, CAS 265669 37 2, epitope peptides, Nucleoprotein 118 126

Send Inquiry